KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In colon cancer, the second most common cause of cancer death, such mutations ...
Cohort 1, osimertinib monotherapy. Cohort 2, a combination of osimertinib and savolitinib therapy. The cutoff date: May 28, 2024. FAS, Full Analysis Set; PD, Progressive disease. [1] Patients with MET ...
A study shows that high levels of negatively charged lipids can lock growth receptors into an overactive state, driving ...
Structural insight into KRAS conformational cycling exposed temporary binding opportunities, overturning the “undruggable” ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
CStone Pharmaceuticals ('CStone,' HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results